LMAT - Dividend announcements

BURLINGTON, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today announced that it has joined the NASDAQ US Broad Dividend Achievers Index. The index is comprised of US securities with at least ten consecutive years of increasing annual regular dividend payments. In 2011, LeMaitre's first year of dividends, the annual payout per share was $0.08. In 2021, LeMaitre paid $0.44 per share, representing 18.6% compounded annual dividend growth over the decade. A further increase was announced in February 2022, bringing the quarterly payout to $0.125 per share, payable on March 24, 2022.George W. LeMaitre, Chairman and Chief

BURLINGTON, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q1 2021 results and announced an $0.11/share quarterly dividend. Q1 2021 Results Sales of $35.9mm, +17% (-5% organic) vs. Q1 2020Op. income of $7.9mm, +83%Op. margin of 22%Net income of $5.9mm, +87%Earnings of $0.28 per diluted share, +83%EBITDA of $10.5mm, +83%Debt paid down $7.0mm to $32.0mm Sales grew in the Americas (+29%) and Asia/Pac (+25%) while Europe/Middle East/Africa (-5%) declined. Sales growth was led by Artegraft, valvulotomes and embolectomy catheters, and was partially offset by CE Mark and COVID related issues. The gross ma

BURLINGTON, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2020 results and announced an $0.11/share quarterly dividend. Q4 2020 Results Sales of $37.5mm, +24% (+3% organic) vs. Q4 2019Op. income of $9.5mm, +94%Op. margin of 25%Net income of $7.0mm, +52%Earnings of $0.34 per diluted share, +51%EBITDA of $11.9mm, +84%Debt paid down $21.5mm to $39.0mm The Company posted sales growth in the Americas (+35%), Asia/Pac (+12%) and Europe/Middle East/Africa (+9%). The three recent acquisitions (Artegraft, CardioCel and Eze-Sit) led growth in Q4 2020. By product, biologic grafts, valvulotomes and embolecto